Thorotrast toxicity: The safety of gadolinium compounds

Netherlands Journal of Medicine

Volumn 65, Issue 8, 2007, Pages 276-278

  Wetzels, J F M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; CERIVASTATIN; CISAPRIDE; FENFLURAMINE; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOXETIC ACID; MIBEFRADIL; NEFAZODONE; ROFECOXIB; TERFENADINE; THORIUM DIOXIDE;

ANGIOSARCOMA; CANCER RISK; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTINUOUS HEMODIALYSIS; DISABILITY; DISEASE SEVERITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEMODIALYSIS PATIENT; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; LIVER NECROSIS; LIVER TOXICITY; LIVER TUMOR; LOW DRUG DOSE; NEPHROGENIC FIBROSING DERMOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTMARKETING SURVEILLANCE; RADIATION EXPOSURE; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; SKIN FIBROSIS; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE;

CARCINOGENS; CONTRAST MEDIA; DRUG TOXICITY; GADOLINIUM; HEMANGIOSARCOMA; HUMANS; LIVER NEOPLASMS; RISK FACTORS; THORIUM DIOXIDE;

EID: 34948861652     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (14)

1. Van Kampen RJW, Erdkamp FLG, Peters FPJ. Thorium dioxide related malignancy of the liver. Neth J Med 2007;65:279-82.
2. Lipshutz GS, Brennan TV, Warren RS. Thorotrast-induced liver neoplasia: a collective review. J Am Coll Surg 2002;195:713-8.
3. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. The safety of newly approved medicines. JAMA 1999;281:1728-34.
4. Fontanarosa PB, Rennie D, De-Angelis CD. Postmarketing surveillance-Lack of vigilance, lack of trust. JAMA 2004;292:2647-50.
5. Roth-Cline MD. Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs. Circulation 2006;113:2253-9.
6. Lexchin J. Drug withdrawals from the Canadian market for safety reasons, 1963-2004. CMAJ 2005;172:765-7.
7. Public assessment report: increased risk of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis and gadolinium-containing MRI contrast agents. www.ismrm.org/special/EMEA3.pdf.
8. FDA Public Health Advisory. http://www.fda.gov/cder/drug/advisory/ gadolium_agents_20061222.htm.
9. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356:1000-1.
10. Ting WW, Seabury-Stone M, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003;139:903-6.
11. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-62.
12. Grobner T. Gadolinium, a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-8.
13. Cheng S, Abramova L, Saab G, et al. Nephrogenic Fibrosing Dermatopathy associated with exposure to gadolinium containing contrast agents in St Louis Missouri, 2002-2006. MMWR 2007;56:137-41.
14. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007;242:647-9.